ClinVar Miner

Submissions for variant NM_014270.5(SLC7A9):c.614dup (p.Asn206fs)

dbSNP: rs745319034
Minimum review status: Collection method:
Minimum conflict level:
ClinVar version:
Total submissions: 10
Download table as spreadsheet
Submitter RCV SCV Clinical significance Condition Last evaluated Review status Method Comment
Eurofins Ntd Llc (ga) RCV000788761 SCV000342240 pathogenic not provided 2016-06-01 criteria provided, single submitter clinical testing
Illumina Laboratory Services, Illumina RCV000286788 SCV000411414 pathogenic Cystinuria 2017-04-28 criteria provided, single submitter clinical testing The SLC7A9 c.614dupA (p.Asn206GlufsTer3) variant, also referred to as c.799insA, has been reported in five studies in a total of 33 individuals with cystinuria, including three homozygotes, eight compound heterozygotes, and 22 heterozygotes with varying disease types (Leclerc et al. 2002; Font-Llitjos et al. 2005; Barbosa et al. 2012; Rhodes et al. 2015; Halbritter et al. 2015). Control data are unavailable for this variant, which is reported at a frequency of 0.00017 in the European (non-Finnish) population of the Exome Aggregation Consortium. The p.Asn206GlufsTer3 variant results in a frameshift, and is predicted to truncate the protein. While cystinuria generally displays an autosomal recessive mode of inheritance, some heterozygous carriers of variants in the SLC7A9 gene have abnormal urinary amino acid patterns and an increased risk of kidney stones (Eggermann et al. 2012). Based on the evidence and due to the potential impact of frameshift variants, the p.Asn206GlufsTer3 variant is classified as pathogenic for cystinuria. This variant was observed by ICSL as part of a predisposition screen in an ostensibly healthy population.
Blueprint Genetics RCV000788761 SCV000927996 pathogenic not provided 2018-10-16 criteria provided, single submitter clinical testing
Invitae RCV000788761 SCV000950666 pathogenic not provided 2023-10-05 criteria provided, single submitter clinical testing This sequence change creates a premature translational stop signal (p.Asn206Glufs*3) in the SLC7A9 gene. It is expected to result in an absent or disrupted protein product. Loss-of-function variants in SLC7A9 are known to be pathogenic (PMID: 11157794, 16838140, 25296721). This variant is present in population databases (rs745319034, gnomAD 0.02%). This premature translational stop signal has been observed in individual(s) with cystinuria in the heterozygous state (PMID: 12371955, 15635077, 16834950, 19782624, 21255007, 25109415, 25296721, 25964309). It has also been observed to segregate with disease in related individuals. This variant is also known as 799insA and c.800-801insA. ClinVar contains an entry for this variant (Variation ID: 288197). For these reasons, this variant has been classified as Pathogenic.
Laboratory for Molecular Medicine, Mass General Brigham Personalized Medicine RCV000286788 SCV000966984 pathogenic Cystinuria 2017-09-15 criteria provided, single submitter clinical testing The p.Asn206GlufsX3 (NM_014270.4 c.614dupA) variant in SLC7A9 (also referred to as c.799insA or c.800?801insA in the literature) has been reported in at least 2 5 heterozygotes, 2 homozygotes, and 2 compound heterozygotes with cystinuria (Le clerc 2002, Font-Llitjos 2005, Barbosa 2012, Rhodes 2015, and Halbritter 2015). Twenty one heterozygotes were noted to have non-type I cystinuria (heterozygotes with moderate to high excretion of cystine in urine and risk of forming urinary tract stones) (Font-Llitjos 2005, Barbosa 2012, Halbritter 2015). This variant has also been reported in ClinVar (Variation ID#288197), as pathogenic by two la boratories. It has been identified in 0.024% (30/126,648) of European chromosom es by the Genome Aggregation Database (gnomAD, http://gnomad.broadinstitute.org; dbSNP rs745319034). This variant is predicted to cause a frameshift, which alte rs the protein?s amino acid sequence beginning at position 206 and leads to a pr emature termination codon 3 amino acids downstream. This alteration is then pred icted to lead to a truncated or absent protein. Loss of function of the SLC7A9 g ene is an established disease mechanism in cystinuria. Variants associated with non-type I cystinuria, such as this variant, are inherited in an autosomal domin ant manner with incomplete penetrance and cause more severe disease in the homoz ygous or compound heterozygous state. In summary, although additional studies a re required to fully establish its clinical significance, the p.Asn206GlufsX3 va riant is pathogenic for cystinuria in an autosomal dominant manner with incompl ete penetrance based on its occurrence in affected individuals and a predicted n ull effect.
Fulgent Genetics, Fulgent Genetics RCV000286788 SCV001752556 pathogenic Cystinuria 2021-06-30 criteria provided, single submitter clinical testing
GeneDx RCV000788761 SCV002015431 pathogenic not provided 2022-10-11 criteria provided, single submitter clinical testing Observed in multiple unrelated patients from different ethnic backgrounds with type II and type III cystinuria or with cystinuria and nephrolithiasis in published literature (Leclerc et al., 2002; Halbritter et al., 2015); Frameshift variant predicted to result in protein truncation or nonsense mediated decay in a gene for which loss-of-function is a known mechanism of disease; This variant is associated with the following publications: (PMID: 12371955, 26990548, 25296721, 30609409, 29431110, 28717662)
Revvity Omics, Revvity Omics RCV000286788 SCV002020729 pathogenic Cystinuria 2023-11-16 criteria provided, single submitter clinical testing
Preventiongenetics, part of Exact Sciences RCV003417906 SCV004107695 pathogenic SLC7A9-related condition 2023-07-20 criteria provided, single submitter clinical testing The SLC7A9 c.614dupA variant is predicted to result in a frameshift and premature protein termination (p.Asn206Glufs*3). This common pathogenic SLC7A9 variant in the heterozygous state has been reported to cause moderate or severe cystinuria in different families, suggesting an autosomal dominant mode of inheritance (reported as 799insA at Leclerc et al. 2002. PubMed ID: 12371955). This variant has also been reported in the homozygous or compound heterozygous state in many unrelated individuals to cause cystinuria (Rhodes et al. 2015. PubMed ID: 25964309; Bisceglia et al. 2010. PubMed ID: 19782624; Barbosa et al. 2011. PubMed ID: 21255007). In summary, the c.614dup is classified as pathogenic.
OMIM RCV000286788 SCV000026328 pathogenic Cystinuria 2002-11-01 no assertion criteria provided literature only

The information on this website is not intended for direct diagnostic use or medical decision-making without review by a genetics professional. Individuals should not change their health behavior solely on the basis of information contained on this website. Neither the University of Utah nor the National Institutes of Health independently verfies the submitted information. If you have questions about the information contained on this website, please see a health care professional.